Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

New Hope in Targeted Treatment for Lung Cancer

New Hope in Targeted Treatment for Lung Cancer

In patients with fourth-stage non-small cell lung cancer, that is, those who have developed metastasis , many targeted drugs have been developed over the last 10 years for treatment. Particularly in the adenocarcinoma subtype, more than half of patients who have never smoked were found eligible for targeted drug treatment, while this rate also reached around 20% in patients who smoked. It is extremely important to perform molecular tests in appropriate patients to determine whether targeted drugs will work, and new targets suitable for the use of targeted drugs are being discovered every day.

ESMO 2016 At the Cancer Congress, patients found to have RET fusion positivity in adenocarcinomas, a type of non-small cell lung cancer, were given the targeted drug Lenvatinib in a trial, and it was found to be very successful. Lenvatinib is a multikinase inhibitor and a drug that stops intracellular growth signals.

RET fusion positivity was detected in 1-2% of all adenocarcinomas. At first glance, these rates may seem very low and insignificant, but when one considers that this corresponds to a human life, its extreme importance becomes apparent.

Lenvatinib was used in 25 patients, and disease was brought under control in 76% of these patients. Although significant treatment-related side effects were observed, these side effects could be controlled, that is, managed, through dose adjustment. Although these study results are not yet sufficient to change our clinical practice, they herald a new ray of hope at our door.

Sources

V. Velcheti, T. Hida, K.L. Reckamp.
Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung.
ESMO 2016, 1204PD

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

New Hope in Targeted Treatment for Lung Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy